Chronicle Journal: Finance

Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance

The company said in an open letter to shareholders, its board of directors are "confident" the drugmakers acquisition of Celgene is the best path forward.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.